XELODA Side Effects

7022494-8 | Disease Recurrence, Platelet Count Decreased
on Sep 30, 2010 Male patient from CHINA , 50 years of age, was diagnosed with colon cancer and was treated with Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: disease recurrence, platelet count decreased. Xeloda dosage: . During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ).

7022462-6 | Back Pain, Disseminated Intravascular Coagulation, Protein Urine Present
Patient was taking Xeloda (View Usage). Patient had the following side effects: back pain (What is back pain?), disseminated intravascular coagulation, protein urine present on Sep 17, 2010 from JAPAN Additional patient health information: Male patient , 65 years of age, was diagnosed with large intestine carcinoma and. Xeloda dosage: Note: C Method.. During the same period patient was treated with AVASTIN (Dosage Is Uncertain.) (View Avastin Review and Avastin Label ), ELPLAT (Dosage Is Uncertain.) (View Elplat Review and Elplat Label ). Patient was hospitalized.

7020497-0 | Bursitis, Chromaturia, Malignant Neoplasm Progression, Musculoskeletal Pain, Urine Odour Abnormal
Adverse event was reported on Sep 21, 2010 by a Female patient taking Xeloda (View Usage) (Dosage: Third Cycle) . Location: BRAZIL , weighting 149.9 lb, After Xeloda was administered, patient had the following side effects: bursitis (What is bursitis?), chromaturia, malignant neoplasm progression, musculoskeletal pain, urine odour abnormal.

7020473-8 | Anaemia, Areflexia, Diabetes Mellitus, Hepatic Steatosis, Hypokalaemia, Hyponatraemia, Inflammation, Oesophageal Candidiasis, Proteinuria
on Sep 20, 2010 Male patient from FRANCE , weighting 169.8 lb, was diagnosed with colon cancer, arrhythmia (What is arrhythmia?) and was treated with Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, areflexia, diabetes mellitus, hepatic steatosis, hypokalaemia, hyponatraemia, inflammation, oesophageal candidiasis, proteinuria. Xeloda dosage: For 14 Days. Six Cycles Were Planned.. During the same period patient was treated with VALSARTAN AND HYDROCHLOROTHIAZIDE (Start: More Than 5 Years. Dose: 160/25 ? Df Daily) (View Valsartan And Hydrochlorothiazide Review and Valsartan And Hydrochlorothiazide Label ), FLECAINIDE ACETATE (Start Date: For More Than 5 Years) (View Flecainide Acetate Review and Flecainide Acetate Label ), EUPANTOL (View Eupantol Review and Eupantol Label ).


7020462-3 | Malignant Neoplasm Progression, Nausea, Palmar-plantar Erythrodysaesthesia Syndrome
on Sep 21, 2010 Female patient from UNITED STATES , weighting 149.9 lb, was diagnosed with pain (What is pain?), nausea (What is nausea?) and was treated with Xeloda (View Usage). Patient had the following side effects: malignant neoplasm progression, nausea (What is nausea?), palmar-plantar erythrodysaesthesia syndrome. Xeloda dosage: . During the same period patient was treated with HYDROCODONE BITARTRATE + ACETAMINOPHEN (View Hydrocodone Bitartrate + Acetaminophen Review and Hydrocodone Bitartrate + Acetaminophen Label ), ONDANSETRON (Frequency: Every 8 Hour As Needed) (View Ondansetron Review and Ondansetron Label ), PROCHLORPERAZINE (View Prochlorperazine Review and Prochlorperazine Label ), PANTOPRAZOLE (View Pantoprazole Review and Pantoprazole Label ).

7018130-7 | Cellulitis, Enterocutaneous Fistula, Small Intestinal Perforation
Patient was taking Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: cellulitis (What is cellulitis?), enterocutaneous fistula, small intestinal perforation on Sep 17, 2010 from JAPAN Additional patient health information: Male patient , weighting 116.8 lb, was diagnosed with rectal cancer recurrent and. Xeloda dosage: . During the same period patient was treated with AVASTIN (View Avastin Review and Avastin Label ), ELPLAT (View Elplat Review and Elplat Label ).

7014754-1 | Circulatory Collapse, Diarrhoea, Malignant Neoplasm Progression, Neutropenia, Pulmonary Oedema, Pyrexia
Adverse event was reported on Sep 17, 2010 by a Male patient taking Xeloda (View Usage) (Dosage: ) was diagnosed with colorectal cancer (What is colorectal cancer?) and. Location: CZECH REPUBLIC , 62 years of age, Patient experienced the following unwanted or unexpected effects: circulatory collapse, diarrhoea, malignant neoplasm progression, neutropenia, pulmonary oedema, pyrexia. During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ), OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.

7014696-1 | Dehydration, Diarrhoea Haemorrhagic, Hypokalaemia, Hyponatraemia
on Sep 22, 2010 Female patient from SPAIN , 53 years of age, was diagnosed with breast cancer stage iv and was treated with Xeloda (View Usage). Patient had the following side effects: dehydration, diarrhoea haemorrhagic, hypokalaemia, hyponatraemia. Xeloda dosage: . During the same period patient was treated with TYVERB (View Tyverb Review and Tyverb Label ).

7014678-X | Gait Disturbance, Guillain-barre Syndrome, Muscular Weakness, Paraesthesia, Paraparesis, Polyneuropathy
on Sep 16, 2010 Male patient from SPAIN , 61 years of age, weighting 121.3 lb, was diagnosed with colon cancer and was treated with Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: gait disturbance, guillain-barre syndrome (What is guillain-barre syndrome?), muscular weakness, paraesthesia, paraparesis, polyneuropathy. Xeloda dosage: . During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ), NOVONORM (View Novonorm Review and Novonorm Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

7014625-0 | Aplasia, Dihydropyrimidine Dehydrogenase Deficiency, Leukopenia, Mucosal Inflammation, Skin Toxicity
Patient was taking Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: aplasia, dihydropyrimidine dehydrogenase deficiency, leukopenia, mucosal inflammation, skin toxicity on Sep 20, 2010 from FRANCE Additional patient health information: Male patient , weighting 145.5 lb, . Xeloda dosage: For 14 Days.

7012711-2 | Chromaturia, Malignant Neoplasm Progression, Musculoskeletal Pain, Urine Odour Abnormal
Adverse event was reported on Sep 14, 2010 by a Female patient taking Xeloda (View Usage) (Dosage: ) . Location: BRAZIL , weighting 149.9 lb, Patient had the following side effects: chromaturia, malignant neoplasm progression, musculoskeletal pain, urine odour abnormal.

7012649-0 | Diarrhoea, Femoral Artery Embolism, Mouth Ulceration, Palmar-plantar Erythrodysaesthesia Syndrome
on Sep 15, 2010 Female patient from POLAND , weighting 132.3 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and was treated with Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: diarrhoea, femoral artery embolism, mouth ulceration, palmar-plantar erythrodysaesthesia syndrome. Xeloda dosage: Frequency: 2 X Day. During the same period patient was treated with ATENOLOL (View Atenolol Review and Atenolol Label ). Patient was hospitalized.

7012644-1 | Nausea, Palmar-plantar Erythrodysaesthesia Syndrome, Rectal Perforation
on Sep 15, 2010 Female patient from JAPAN , weighting 74.96 lb, was diagnosed with rectal cancer metastatic and was treated with Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: nausea (What is nausea?), palmar-plantar erythrodysaesthesia syndrome, rectal perforation. Xeloda dosage: . During the same period patient was treated with AVASTIN (View Avastin Review and Avastin Label ), ELPLAT (View Elplat Review and Elplat Label ), VOLTAREN (View Voltaren Review and Voltaren Label ), LOXOPROFEN SODIUM (View Loxoprofen Sodium Review and Loxoprofen Sodium Label ), DECADRON (Dose Form: Uncertainty) (View Decadron Review and Decadron Label ), NORVASC (View Norvasc Review and Norvasc Label ), GANATON (View Ganaton Review and Ganaton Label ), MAGLAX (View Maglax Review and Maglax Label ).

7001518-8 | Diarrhoea
Patient was taking Xeloda (View Usage). Patient had the following side effects: diarrhoea on Sep 15, 2010 from AUSTRALIA Additional patient health information: Male patient , 78 years of age, was diagnosed with colorectal cancer (What is colorectal cancer?) and. Xeloda dosage: . Patient was hospitalized.

6992609-6 | Gait Disturbance, Metastases To Lung, Oedema Peripheral, Pain In Extremity, Palmar-plantar Erythrodysaesthesia Syndrome, Skin Chapped, Skin Haemorrhage
Adverse event was reported on Sep 09, 2010 by a Female patient taking Xeloda (View Usage) (Dosage: ) was diagnosed with metastases to lung, hypertension and. Location: BRAZIL , weighting 152.1 lb, After Xeloda was administered, patient had the following side effects: gait disturbance, metastases to lung, oedema peripheral, pain in extremity, palmar-plantar erythrodysaesthesia syndrome, skin chapped, skin haemorrhage. During the same period patient was treated with HYDROCHLOROTHIAZIDE (25 Mg At Morning) (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), CAPTOPRIL (At Morning) (View Captopril Review and Captopril Label ).

6988174-X | Interstitial Lung Disease
on Sep 07, 2010 Female patient from FRANCE , 76 years of age, was treated with Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: interstitial lung disease. Xeloda dosage: .

6988166-0 | Altered State Of Consciousness, Leukoencephalopathy
on Sep 08, 2010 Female patient from JAPAN , weighting 83.78 lb, was diagnosed with colon cancer metastatic and was treated with Xeloda (View Usage). Patient had the following side effects: altered state of consciousness, leukoencephalopathy. Xeloda dosage: . During the same period patient was treated with ELPLAT (Uncertainity) (View Elplat Review and Elplat Label ), MORPHINE HYDROCHLORIDE (Dosage Form: Peroral Liquid Preparation) (View Morphine Hydrochloride Review and Morphine Hydrochloride Label ), LOXOPROFEN (View Loxoprofen Review and Loxoprofen Label ), ZYPREXA (View Zyprexa Review and Zyprexa Label ).

6985512-9 | Haematotoxicity, Nausea, Neurotoxicity, Skin Toxicity
Patient was taking Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: haematotoxicity, nausea (What is nausea?), neurotoxicity, skin toxicity on Sep 07, 2010 from CZECH REPUBLIC Additional patient health information: Female patient , 45 years of age, was diagnosed with breast cancer (What is breast cancer?) and. Xeloda dosage: 2000mgm2 Per Day. During the same period patient was treated with TYVERB (1250mg Per Day) (View Tyverb Review and Tyverb Label ), NAVELBINE (View Navelbine Review and Navelbine Label ), TAXOTERE (View Taxotere Review and Taxotere Label ), TAXOL (View Taxol Review and Taxol Label ), HERCEPTIN (View Herceptin Review and Herceptin Label ).

6985229-0 | Cerebral Haemorrhage
Adverse event was reported on Sep 04, 2010 by a Male patient taking Xeloda (View Usage) (Dosage: ) . Location: GERMANY , 42 years of age, Patient experienced the following unwanted or unexpected effects: cerebral haemorrhage. During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.

6980240-8 | Hiatus Hernia, Hiccups, Myalgia
on Sep 02, 2010 Female patient from JAPAN , weighting 110.2 lb, was diagnosed with colon cancer recurrent and was treated with Xeloda (View Usage). Patient had the following side effects: hiatus hernia, hiccups, myalgia. Xeloda dosage: Note: 2 Weeks Administration Followed By 1 Week Rest.. During the same period patient was treated with AVASTIN (View Avastin Review and Avastin Label ), ELPLAT (Dosage Is Uncertain.) (View Elplat Review and Elplat Label ). Patient was hospitalized.

6980226-3 | Acute Respiratory Failure, Decreased Appetite, Dizziness, Nausea, Palmar-plantar Erythrodysaesthesia Syndrome
on Sep 06, 2010 Male patient from JAPAN , weighting 154.3 lb, was diagnosed with colon cancer recurrent and was treated with Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: acute respiratory failure, decreased appetite, dizziness (What is dizziness?), nausea (What is nausea?), palmar-plantar erythrodysaesthesia syndrome. Xeloda dosage: It Was Reported That One Administering Weekly Holiday Medicine For Two Weeks.. During the same period patient was treated with ELPLAT (Form: Injection, Note: Dosage Is Uncertain) (View Elplat Review and Elplat Label ).

6978577-1 | Cardiac Tamponade, Cardiomegaly, Decreased Appetite, Lymphangiosis Carcinomatosa, Malaise, Malignant Neoplasm Progression, Nausea, Pericardial Effusion
Patient was taking Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac tamponade, cardiomegaly, decreased appetite, lymphangiosis carcinomatosa, malaise, malignant neoplasm progression, nausea (What is nausea?), pericardial effusion on Sep 01, 2010 from JAPAN Additional patient health information: Female patient , 52 years of age, was diagnosed with breast cancer metastatic and. Xeloda dosage: . Patient was hospitalized.

6976989-3 | Prinzmetal Angina
Adverse event was reported on Sep 01, 2010 by a Female patient taking Xeloda (View Usage) (Dosage: ) . Location: GERMANY , 55 years of age, weighting 242.5 lb, Patient had the following side effects: prinzmetal angina. Patient was hospitalized.

6976963-7 | Ileus, Malignant Neoplasm Progression, Rectal Cancer, Rectal Haemorrhage
on Sep 01, 2010 Male patient from GERMANY , weighting 176.4 lb, was treated with Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: ileus, malignant neoplasm progression, rectal cancer, rectal haemorrhage. Xeloda dosage: Between 800 And 1200 Mg/m2 Twice/day.. During the same period patient was treated with CETUXIMAB (View Cetuximab Review and Cetuximab Label ), ZOMETA (View Zometa Review and Zometa Label ). Patient was hospitalized.

6970518-6 | Anaemia, Blood Bilirubin Increased, Muscle Haemorrhage, Prothrombin Time Ratio Increased, Retroperitoneal Haemorrhage, Subdural Haematoma
on Aug 31, 2010 Male patient from JAPAN , weighting 132.3 lb, was diagnosed with colon cancer and was treated with Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, blood bilirubin increased, muscle haemorrhage, prothrombin time ratio increased, retroperitoneal haemorrhage, subdural haematoma. Xeloda dosage: Note: 2 Weeks Administration Followed By 1week Rest.. During the same period patient was treated with WARFARIN (Dosage Is Uncertain) (View Warfarin Review and Warfarin Label ), SIGMART (View Sigmart Review and Sigmart Label ), MARZULENE (Form: Granulated Powder) (View Marzulene Review and Marzulene Label ), LUPRAC (View Luprac Review and Luprac Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), MICARDIS (View Micardis Review and Micardis Label ).

6968257-0 |
Patient was taking Xeloda (View Usage). on Aug 27, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 343.9 lb, . Xeloda dosage: . During the same period patient was treated with NEUPOGEN (View Neupogen Review and Neupogen Label ), NEULASTA (View Neulasta Review and Neulasta Label ), ANZEMET (View Anzemet Review and Anzemet Label ), DECADRON (View Decadron Review and Decadron Label ).

6960857-7 | Ileus, Malignant Neoplasm Progression
Adverse event was reported on Aug 25, 2010 by a Male patient taking Xeloda (View Usage) (Dosage: 3300 Mg/day For The First 14 Days.) . Location: GERMANY , weighting 138.9 lb, After Xeloda was administered, patient had the following side effects: ileus, malignant neoplasm progression. During the same period patient was treated with OXALIPLATIN (70 Mg On Day 1 And Day 8. First Administration Was On 18 Mar 2010.) (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.

6960686-4 | Altered State Of Consciousness, Leukoencephalopathy
on Aug 24, 2010 Female patient from JAPAN , weighting 83.78 lb, was diagnosed with colon cancer metastatic and was treated with Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: altered state of consciousness, leukoencephalopathy. Xeloda dosage: . During the same period patient was treated with ELPLAT (Uncertainity) (View Elplat Review and Elplat Label ), MORPHINE HYDROCHLORIDE (Dosage Form: Peroral Liquid Preparation) (View Morphine Hydrochloride Review and Morphine Hydrochloride Label ), LOXOPROFEN (View Loxoprofen Review and Loxoprofen Label ), ZYPREXA (View Zyprexa Review and Zyprexa Label ).

6958386-X | Malignant Neoplasm Progression, Palmar-plantar Erythrodysaesthesia Syndrome
on Aug 25, 2010 Female patient from UNITED STATES , weighting 218.0 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Xeloda (View Usage). Patient had the following side effects: malignant neoplasm progression, palmar-plantar erythrodysaesthesia syndrome. Xeloda dosage: Taken For 2 Weeks.

6955869-3 | Diarrhoea, Femoral Artery Embolism, Mouth Ulceration, Palmar-plantar Erythrodysaesthesia Syndrome
Patient was taking Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: diarrhoea, femoral artery embolism, mouth ulceration, palmar-plantar erythrodysaesthesia syndrome on Aug 23, 2010 from POLAND Additional patient health information: Female patient , weighting 132.3 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and. Xeloda dosage: Frequency: 2 X Day. Patient was hospitalized.

6955746-8 | Brain Injury, Locked-in Syndrome, Loss Of Consciousness, Ventricular Fibrillation
Adverse event was reported on Aug 20, 2010 by a Female patient taking Xeloda (View Usage) (Dosage: 2000 Mg In Morning 1500 Mg In Evening) . Location: CZECH REPUBLIC , 40 years of age, Patient experienced the following unwanted or unexpected effects: brain injury, locked-in syndrome, loss of consciousness, ventricular fibrillation. During the same period patient was treated with AVASTIN (View Avastin Review and Avastin Label ), OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized and became disabled.

6955594-9 | Diarrhoea, Ileus
on Aug 20, 2010 Female patient from AUSTRALIA , 50 years of age, was diagnosed with colorectal cancer (What is colorectal cancer?) and was treated with Xeloda (View Usage). Patient had the following side effects: diarrhoea, ileus. Xeloda dosage: . During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ).

6945458-9 | Haemolytic Anaemia, International Normalised Ratio Increased
on Aug 19, 2010 Female patient from GERMANY , weighting 136.7 lb, was diagnosed with metastatic gastric cancer and was treated with Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: haemolytic anaemia, international normalised ratio increased. Xeloda dosage: On Days 1 - 14 Of Each 21-day-cycle. During the same period patient was treated with HERCEPTIN (View Herceptin Review and Herceptin Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ).

6945410-3 | Anaemia, Enterocolitis, Large Intestine Perforation
Patient was taking Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, enterocolitis, large intestine perforation on Aug 19, 2010 from JAPAN Additional patient health information: Female patient , weighting 125.7 lb, was diagnosed with colon cancer metastatic, systemic lupus erythematosus and. Xeloda dosage: . During the same period patient was treated with NAIXAN (View Naixan Review and Naixan Label ), AVASTIN (View Avastin Review and Avastin Label ), PREDONINE (View Predonine Review and Predonine Label ), ELPLAT (View Elplat Review and Elplat Label ), GASTER D (View Gaster D Review and Gaster D Label ), FRANDOL (View Frandol Review and Frandol Label ), ALFAROL (View Alfarol Review and Alfarol Label ), ADALAT CC (Form: Sustained Release Tablet) (View Adalat Cc Review and Adalat Cc Label ).

6945391-2 | Conjunctivitis, Malignant Neoplasm Progression
Adverse event was reported on Aug 20, 2010 by a Female patient taking Xeloda (View Usage) (Dosage: ) was diagnosed with antiemetic supportive care and. Location: GERMANY , weighting 136.7 lb, Patient had the following side effects: conjunctivitis, malignant neoplasm progression. During the same period patient was treated with HERCEPTIN (View Herceptin Review and Herceptin Label ), MCP (View Mcp Review and Mcp Label ).

6938771-2 | Lymphangiosis Carcinomatosa, Metastases To Meninges
on Aug 11, 2010 Male patient from GERMANY , weighting 176.4 lb, was diagnosed with gastric cancer and was treated with Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: lymphangiosis carcinomatosa, metastases to meninges. Xeloda dosage: The 5th Cycle According To Eox Protocol. During the same period patient was treated with EPIRUBICIN (The 5th Cycle According To Eox Protocol) (View Epirubicin Review and Epirubicin Label ), OXALIPLATINE (The 5th Cycle According To Eox Protocol) (View Oxaliplatine Review and Oxaliplatine Label ).

6936674-0 | Acute Coronary Syndrome, Troponin T Increased
on Aug 20, 2010 Female patient from ITALY , 57 years of age, was diagnosed with adenocarcinoma and was treated with Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: acute coronary syndrome, troponin t increased. Xeloda dosage: . During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.

6936637-5 | Fibrosis, Gastrointestinal Stoma Complication
Patient was taking Xeloda (View Usage). Patient had the following side effects: fibrosis, gastrointestinal stoma complication on Aug 13, 2010 from SLOVENIA Additional patient health information: Male patient , weighting 167.6 lb, . Xeloda dosage: . During the same period patient was treated with AMPRIL (5 Mg,1tab/day) (View Ampril Review and Ampril Label ), CORDIPIN (20 Mg , 1 Tab /day) (View Cordipin Review and Cordipin Label ), CONTROLOC (20 Mg 1tab/day) (View Controloc Review and Controloc Label ). Patient was hospitalized.

6933904-6 | Hypoaesthesia, Joint Contracture
Adverse event was reported on Aug 10, 2010 by a Male patient taking Xeloda (View Usage) (Dosage: Note: It Is One Administering Weekly Holiday Medicine For Two Weeks) was diagnosed with colon cancer metastatic and. Location: JAPAN , weighting 143.3 lb, After Xeloda was administered, patient had the following side effects: hypoaesthesia, joint contracture. During the same period patient was treated with ELPLAT (Dose Decreased) (View Elplat Review and Elplat Label ), FERROMIA (View Ferromia Review and Ferromia Label ), PYDOXAL (Dose Form: Uncertainty) (View Pydoxal Review and Pydoxal Label ).

6932289-9 | Optic Ischaemic Neuropathy
on Aug 12, 2010 Male patient from NETHERLANDS , weighting 202.8 lb, was treated with Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: optic ischaemic neuropathy. Xeloda dosage: . During the same period patient was treated with OXALIPLATIN (Form, Route And Frequency: Not Provided) (View Oxaliplatin Review and Oxaliplatin Label ).

6932288-7 | Diarrhoea, Face Oedema, Palmar-plantar Erythrodysaesthesia Syndrome
on Aug 11, 2010 Female patient from ALGERIA , 40 years of age, was treated with Xeloda (View Usage). Patient had the following side effects: diarrhoea, face oedema, palmar-plantar erythrodysaesthesia syndrome. Xeloda dosage: .

6932280-2 | Asthenia, Dermatomyositis, Jaundice, Mucosal Inflammation, Palmar-plantar Erythrodysaesthesia Syndrome, Skin Toxicity
Patient was taking Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: asthenia, dermatomyositis, jaundice (What is jaundice?), mucosal inflammation, palmar-plantar erythrodysaesthesia syndrome, skin toxicity on Aug 09, 2010 from TUNISIA Additional patient health information: Female patient , 47 years of age, . Xeloda dosage: Dose: 9 Cp (500 Mg). During the same period patient was treated with FOLFOX B (View Folfox-b Review and Folfox-b Label ).

6932268-1 | Colitis Ischaemic, Haemorrhage, Palmar-plantar Erythrodysaesthesia Syndrome
Adverse event was reported on Aug 12, 2010 by a Female patient taking Xeloda (View Usage) (Dosage: ) was diagnosed with large intestine carcinoma, psychosomatic disease and. Location: JAPAN , 64 years of age, Patient experienced the following unwanted or unexpected effects: colitis ischaemic, haemorrhage, palmar-plantar erythrodysaesthesia syndrome. During the same period patient was treated with ELPLAT (Note: Dosage Is Uncertain.) (View Elplat Review and Elplat Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ). Patient was hospitalized.

6932258-9 | Diarrhoea, Face Oedema, Palmar-plantar Erythrodysaesthesia Syndrome
on Aug 11, 2010 Male patient from ALGERIA , 45 years of age, was treated with Xeloda (View Usage). Patient had the following side effects: diarrhoea, face oedema, palmar-plantar erythrodysaesthesia syndrome. Xeloda dosage: Frequency: Per Cure..

6930371-3 | Liver Disorder
on Aug 10, 2010 Male patient from JAPAN , weighting 114.6 lb, was diagnosed with colon cancer and was treated with Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: liver disorder. Xeloda dosage: . During the same period patient was treated with PYDOXAL (Reported As Pydoxal Tab(pyridoxal Phosphate).) (View Pydoxal Review and Pydoxal Label ), PROTECADIN (View Protecadin Review and Protecadin Label ), PANTOSIN (Reported As Pantosin(pantethine). Form:uncertainty) (View Pantosin Review and Pantosin Label ), MAGNESIUM OXIDE (Form: Peroral Agent.) (View Magnesium Oxide Review and Magnesium Oxide Label ). Patient was hospitalized.

6930312-9 | Aspiration, Cardio-respiratory Arrest, Dihydropyrimidine Dehydrogenase Deficiency, Disseminated Intravascular Coagulation, Enterocolitis, Metabolic Acidosis, Mucosal Inflammation, Pancytopenia
Patient was taking Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: aspiration, cardio-respiratory arrest, dihydropyrimidine dehydrogenase deficiency, disseminated intravascular coagulation, enterocolitis, metabolic acidosis, mucosal inflammation, pancytopenia on Aug 09, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 115.1 lb, was diagnosed with rectal cancer and. Xeloda dosage: . During the same period patient was treated with ESCITALOPRAM (View Escitalopram Review and Escitalopram Label ), PROGESTERONE (View Progesterone Review and Progesterone Label ), BUPROPION HCL (View Bupropion Hcl Review and Bupropion Hcl Label ).

6928328-1 | Loss Of Consciousness, Ventricular Fibrillation, Vomiting
Adverse event was reported on Aug 10, 2010 by a Male patient taking Xeloda (View Usage) (Dosage: ) was diagnosed with colon cancer, diabetes mellitus and. Location: GERMANY , 61 years of age, Patient had the following side effects: loss of consciousness, ventricular fibrillation, vomiting. During the same period patient was treated with METFORMIN (View Metformin Review and Metformin Label ). Patient was hospitalized.

6928304-9 | Bone Marrow Failure, Mucocutaneous Rash, Multi-organ Failure, Neutropenic Sepsis
on Aug 12, 2010 Male patient from UNITED KINGDOM , 47 years of age, weighting 185.2 lb, was treated with Xeloda (View Usage). After Xeloda was administered, patient had the following side effects: bone marrow failure, mucocutaneous rash, multi-organ failure, neutropenic sepsis. Xeloda dosage: .

6928250-0 | Rash, Stomatitis Necrotising
on Aug 12, 2010 Male patient from RUSSIAN FEDERATION , 60 years of age, was treated with Xeloda (View Usage). Patient experienced the following unwanted or unexpected effects: rash (What is rash?), stomatitis necrotising. Xeloda dosage: . During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ).

6925505-0 | Dermatomyositis, Palmar-plantar Erythrodysaesthesia Syndrome
Patient was taking Xeloda (View Usage). Patient had the following side effects: dermatomyositis, palmar-plantar erythrodysaesthesia syndrome on Aug 09, 2010 from TUNISIA Additional patient health information: Male patient , 66 years of age, . Xeloda dosage: Dose: 3 Cp (500 Mg).